Clinical Trial Update: Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial） [Phase 2]

View source ↗

Summary

A Phase 2 trial (CRIS-2) is evaluating neoadjuvant chemoradiotherapy followed by immunotherapy and surgery for resectable esophageal squamous cell carcinoma. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING